Emergent Biosolutions EBS Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's change in deferred revenue?
- Emergent Biosolutions (EBS) reported change in deferred revenue of $3.2M in Q1 2026.
- How has Emergent Biosolutions's change in deferred revenue changed year-over-year?
- Emergent Biosolutions's change in deferred revenue increased by 1166.7% year-over-year, from -$300K to $3.2M.
- What is the long-term trend for Emergent Biosolutions's change in deferred revenue?
- Over 3 years (2021 to 2025), Emergent Biosolutions's change in deferred revenue has grown at a -45.3% compound annual growth rate (CAGR), from -$31.8M to $5.2M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.